by Jordana Choucair | Nov 15, 2022 | Life Sciences
Moderna announced that its new omicron-targeted COVID-19 booster shot performs better against omicron subvariants. New data from a Phase 2-3 clinical trial shows that the vaccine triggered antibody responses against the BA.4 and BA.5 omicron subvariants that were on...
by Jordana Choucair | Nov 4, 2022 | Life Sciences
Pfizer Inc. said that a new study shows its updated COVID-19 booster, developed with BioNTech SE, increased antibodies for adults 55 and over compared with an extra dose of the original vaccine. The Food and Drug Administration (FDA) said that the new data should help...
by Jordana Choucair | Nov 1, 2022 | Life Sciences
Pfizer today announced promising topline results of a late-stage clinical trial for an experimental respiratory syncytial virus (RSV) vaccine. The vaccine would offer protection to infants from birth by vaccinating women while they’re still pregnant. The vaccine...
by Jordana Choucair | Oct 25, 2022 | Life Sciences
Juul Labs Inc. is discussing a bailout with two of its top shareholders in an effort to avert a bankruptcy filing. The bailout option would position Juul to stay in business and fight the Food and Drug Administration’s (FDA) paused ban to keep the...
by Jordana Choucair | Oct 24, 2022 | Life Sciences
Pfizer plans to increase the price of its COVID-19 vaccine to between $110 to $130 per dose once the U.S. government’s purchasing program ends early next year. The price is roughly four times what the federal government pays per dose ($30). According to a Pfizer...
by Jordana Choucair | Oct 24, 2022 | Life Sciences
Peter Marks, the Food and Drug Administration’s vaccines chief, said in an interview that he’s worried about the possibility of deploying another COVID-19 booster before next September or October because of the speed at which the virus is evolving. Marks...
Recent Comments